Tb in the immunocompromised host

European Respiratory Monograph

Volumn 58, Issue , 2012, Pages 230-241

  Sester, Martina ^a   Bumbacea, Dragos ^b,c   Duarte, Raquel ^b   Lange, Christoph ^d,e,f  

^a SAARLAND UNIVERSITY   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c Research Center Borstel   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f Centro de Diagnostico Pneumologico de Vila Nova de Gaia   (Portugal)

Author keywords

End stage renal disease; Hiv infection; Hiv mycobacterium tuberculosis co infection; Immunosuppression; Transplantation; Tumour necrosis factor antagonist therapy

Indexed keywords

EID: 84870808337     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10024011     Document Type: Article

References (77)

1. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393-422
2. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol 2012; 7: 353-384
3. UNAIDS. Global report. UNAIDS report on the global AIDS epidemic 2010. Geneva, UNAIDS, 2010
4. World Health Organization. Global Tuberculosis Control report. WHO report 2011. Geneva, WHO, 2011
5. Sester M, Giehl C, McNerney R, et al. Challenges and perspectives for improved management of HIV/ Mycobacterium tuberculosis co-infection. Eur Respir J 2010; 36: 1242-1247
6. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012; [Epub ahead of print DOI: 10.1183/09031936.00000712].
7. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27: 1266-1277
8. Subramanian A, Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl. 4, S57-S62
9. Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donorderived infections consensus conference report. Am J Transplant 2012; 12: 2288-2300
10. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-1665
11. Lee J, Lee MH, Kim WS, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol 2004; 79: 185-188
12. Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010; 5: 1114-1122
13. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210
14. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206
15. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1436-1439
16. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127
17. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992
18. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376
19. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-3022
20. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379
21. Wang JY, Lee LN, Lai HC, et al. Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis 2007; 196: 281-288
22. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179
23. Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012; 54: 784-791
24. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855
25. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011; pii: 980594
26. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685
27. Barber DL, Mayer-Barber KD, Antonelli LR, et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 2010; 116: 3485-3493
28. Lapadula G, Soria A, Bandera A, et al. Unmasking tuberculosis in the era of antiretroviral treatment. Eur Respir J 2012; 39: 1064-1075
29. Schuetz A, Dirks J, Sester U, et al. Pathogen prevalence may determine maintenance of antigen-specific T-cell responses in HIV-infected individuals. AIDS 2012; 26: 695-700
30. Girndt M, Sester U, Kaul H, et al. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998; 9: 1689-1696
31. Sester U, Sester M, Heine G, et al. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408
32. Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59: 1382-1389
33. Lim WH, Kireta S, Leedham E, et al. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007; 72: 1138-1148
34. Girndt M, Sester M, Sester U, et al. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001; 78: S206-S211
35. Sterling KA, Eftekhari P, Girndt M, et al. The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat Rev Nephrol 2012; 8: 403-412
36. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-c-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra102
37. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001; 345: 1098-1104
38. Lin PL, Plessner HL, Voitenok NN, et al. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 2007; 12: 22-25
39. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119: 1167-1177
40. Lange C, Mori T. Advances in the diagnosis of tuberculosis. Respirology 2010; 15: 220-240
41. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015
42. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184: 132-140
43. Jafari C, Kessler P, Sotgiu G, et al. Impact of a Mycobacterium tuberculosis-specific interferon-c release assay in bronchoalveolar lavage fluid for a rapid diagnosis of tuberculosis. J Intern Med 2011; 270: 254-262
44. Strassburg A, Jafari C, Ernst M, et al. Rapid diagnosis of pulmonary TB by BAL enzyme-linked immunospot assay in an immunocompromised host. Eur Respir J 2008; 31: 1132-1135
45. Sester M, Sotgiu G, Lange C, et al. Interferon-c release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111
46. Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trials group study. Am J Respir Crit Care Med 2009; 180: 666-673
47. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973
48. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364: 1441-1448
49. Sester M, van Leth F, Girardi E, et al. Head-to-head analysis of IGRAs and skin-testing in immunocompromised patients: Interim analysis of a multicenter TBNET study. Eur Respir J 2010; 36: Suppl. 54, 370s-371s.
50. Sester M, Sester U, Clauer P, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004; 65: 1826-1834
51. Lange C, Rieder HL. Intention to test is intention to treat. Am J Respir Crit Care Med 2011; 183: 3-4
52. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171
53. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711
54. Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatr Respir Rev 2011; 12: 22-26
55. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010; 90: 695-704
56. Holty JE, Gould MK, Meinke L, et al. Tuberculosis in liver transplant recipients: a systematic review and metaanalysis of individual patient data. Liver Transpl 2009; 15: 894-906
57. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761
58. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166
59. American Thoracic society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247
60. World Health Organization. Guidelines for treatment of tuberculosis. Geneva, WHO, 2010
61. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751
62. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299
63. Kumar A, Kumar AM, Gupta D, et al. Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues. Int J Tuberc Lung Dis 2012; 16: 573-578
64. Tuberculosis Research Centre, India. A randomized controlled clinical trial comparing daily vs. intermittent 6- month short course chemotherapy in reducing failures & emergence of acquired rifampicin resistance (ARR) in patients with HIV and pulmonary tuberculosis. http://clinicaltrials.gov/show/NCT00933790 Date last accessed: September 25, 2012. Date last updated: October 28, 2011
65. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77
66. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53: 716-724
67. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706
68. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-1501
69. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491
70. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50: Suppl. 3, S223-S230
71. Calligaro G, Meintjes G, Mendelson M. Pulmonary manifestations of the immune reconstitution inflammatory syndrome. Curr Opin Pulm Med 2011; 17: 180-188
72. Barber DL, Andrade BB, Sereti I, et al. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012; 10: 150-156
73. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-261
74. Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis 2011; 53: 168-176
75. Rivoisy C, Amrouche L, Carcelain G, et al. Paradoxical exacerbation of tuberculosis after TNFa antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 2011; 78: 312-315
76. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390
77. Sun HY, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis 2009; 22: 394-402.